

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purpose only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of the Company.



天津泰達生物醫學工程股份有限公司

Tianjin TEDA Biomedical Engineering Company Limited

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 8189)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE

Reference is made to the announcement (the “**Announcement**”) dated 9 February 2018 of Tianjin TEDA Biomedical Engineering Company Limited (the “**Company**”) in relation to the proposed issue of Subscription Shares to the Subscribers under the General Mandate. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as defined in the Announcement.

Further to the information disclosed in the Announcement, the Company would like to supplement the following additional information of the identity of the Subscribers and the number of Subscription Shares to be issued to each of them:

Name of Subscribers	Number of Subscription Shares
Precious Gem International Development Limited (寶瑞國際發展有限公司), a company incorporated in Hong Kong with limited liability	80,000,000
Easy Goal Enterprises Limited (輝賢企業有限公司), a company incorporated in Hong Kong with limited liability	69,500,000
Bright Fortune Enterprises Development Limited (昇暉企業發展有限公司), a company incorporated in Hong Kong with limited liability	43,000,000

Name of Subscribers	Number of Subscription Shares
Keen Bright Holdings Limited (建明控股有限公司), a company incorporated in the British Virgin Islands with limited liability	3,000,000
Li Wai Chuen (李偉銓), a Hong Kong citizen	2,000,000
Yang Ru, an Australia citizen	2,000,000

The Subscription Agreements may be terminated pursuant to the termination provisions contained therein. In addition, completion of the Subscription is subject to fulfillment of the conditions under each of the Subscription Agreements. As the Subscription may or may not proceed, Shareholders and potential investors are reminded to exercise caution when dealing in the Shares.

By order of the Board
Tianjin TEDA Biomedical Engineering Company Limited
Sun Li
Chairman

Tianjin, the PRC
12 February 2018

As at the date of this announcement, the executive Directors of the Company are Sun Li, Hao Zhihui and Liu Renmu; the non-executive Directors of the Company are Cao Aixin, Feng Enqing, and Li Ximing; the independent non-executive Directors of the Company are Li Xudong, Wang Yongkang and Gao Chun.

This announcement, for which the directors are willing to collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief that the information contained in this announcement is accurate and complete in all material respects and is not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the GEM website at www.hkgem.com on the “Latest Company Announcements” page for 7 days from the date of its posting, and it will also be published and remain on the website of the Company at www.bioteda.com.